PURPOSE: To evaluate the effect of postoperative topical @entity1138 ( @entity1139 ) eye drops in endoscopic (dacryocystorhinostomy) DCR and compare them with intraoperative @entity1139 soaking. DESIGN: Retrospective, nonrandomized, interventional case series. METHODS: One hundred and sixty cases of endoscopic DCR with a single surgeon for primary nasolacrimal duct obstruction (NLDO) were included. Cases were divided into three groups. Group 1 was treated with intraoperative application of 0.02  % @entity1139 for 5  min. Group 2 was treated with 0.02  % @entity1139 eye drops for 5  days after surgery, without intraoperative application of @entity1139 . Group 3 was the control group of cases without the use of @entity1139 . Each group was evaluated for surgical success, presence of complications including @entity738 , @entity5862 , and tube-induced @entity32 , and the adverse effect of the @entity1139 at least 6  months after the surgery. RESULTS: The success rate showed no significant difference among the three groups (P   =   .122, chi-square analysis). In the analysis between the two groups, although the success rate of Group 2 appeared not to be statistically different compared with that of Group 1 (P   =   .419, chi-square analysis), Group 2 had a statistically higher success rate for surgery than Group 3 (P   =   .041, chi-square analysis). The presence of @entity738 was significantly lower in Group 1 than in the other two groups (P   =   .022, chi-square analysis). @entity5862 and @entity1346 tube-induced @entity32 were not significantly different (P   =   .308, P   =   .881, chi-square analysis). There were no adverse effects associated with intraoperative or postoperative @entity1139 application. CONCLUSION: Use of postoperative topical 0.02  % @entity1139 is a safe and effective adjunctive modality to increase the success rate of endoscopic DCR.

Efficacy of postoperative XXXX eye drops on the clinical outcome in endoscopic dacryocystorhinostomy.

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity738 :: ('MESH:D006099', 'Disease') :: ['granuloma'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin-C'] @entity1139 :: ('CHEBI:27504', 'Chemical') :: ['MMC'] @entity1346 :: ('MESH:D012828', 'Chemical') :: ['silicone'] @entity5862 :: ('MESH:D006175', 'Disease') :: ['Synechiae', 'synechiae']
@entity1138 :: (MESH:D016685,Chemical) :: ['mitomycin-C']
